Latest Regulatory News

Cadoux has wrapped up its first drilling program at the Wimmera Mineral Sands project in Victoria, setting the stage for downstream rare earth processing with Minhub’s Darwin plant feasibility study progressing.

Ora Banda Mining (ASX:OBM) reported a substantial expansion of its Mineral Resources and Ore Reserves at the Davyhurst Gold Project, driven by exploration success and significant drilling investment.

Great Western Exploration has kicked off a reverse circulation drilling campaign at its promising Juggernaut copper-gold targets, with assay results from Diorama aircore drilling expected soon. The company also plans potash monitoring at Lake Way and faces pending tenement forfeiture hearings.

Resolution Minerals has completed 16 diamond core holes totalling 4,470 metres at its Golden Gate South prospect in Idaho, progressing one third of its 2026 drill program aimed at defining gold and tungsten mineralisation.

Paradigm Biopharmaceuticals has secured US$3 million in its latest tranche under a US$27 million convertible note facility, bolstering funding for its global Phase 3 trial of injectable pentosan polysulfate sodium in knee osteoarthritis.

Biotron Limited has met the first milestone in its Sedarex acquisition by securing pivotal regulatory feedback from the European Medicines Agency, charting a clearer path for its next-generation anaesthetic SedRx.

Arafura Rare Earths has secured $361.5 million before costs through a combined placement and share purchase plan, issuing approximately 44.4 million new shares under the SPP and leaving a notable shortfall.

BPH Global has kicked off direct seaweed exports to China, reporting AUD 535,895 in sales for the latest trading period and expanding its footprint beyond Indonesia.

ABx Group’s ALCORE subsidiary has begun civil construction at its Bell Bay pilot plant, advancing a novel process to produce hydrogen fluoride from aluminium smelter by-products, addressing Australia’s dependence on imports.

State Gas Limited clears a year-long ATO review to access $4.1 million in R&D tax concessions, enabling debt repayment and bolstering cash reserves. Meanwhile, independent certification of 30.2 petajoules of 2P gas reserves at Rolleston West strengthens its development prospects.

Vectus Biosystems has appointed Cardinal Health Regulatory Services as its US regulatory agent to manage FDA submissions for its lead fibrosis drug VB0004, marking a pivotal step towards clinical development in the US.

Island Pharmaceuticals has secured a critical collaboration with Texas Biomedical Research Institute to advance dose optimisation for its antiviral Galidesivir, targeting Marburg Virus Disease under the FDA Animal Rule. This second phase complements ongoing USAMRIID efforts and aims to de-risk pivotal study design with data from 32 non-human primates.